Tirasemtiv: Completed Phase III enrollment

Cytokinetics completed enrollment of >700 patients in the international Phase III VITALITY-ALS trial evaluating 3 dose levels of twice-daily oral tirasemtiv. Patients receive twice-daily 125 mg tirase...